Hospital eye service follow-up clinics maintain better diagnostic accuracy for active lesions<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 29, 2024 (HealthDay News) — No home-monitoring vision test has the diagnostic accuracy of hospital eye service follow-up clinics to identify active neovascular age-related macular degeneration (nAMD), according to a study published online April 25 in JAMA Ophthalmology<\/em>.<\/p>\n Ruth E. Hogg, Ph.D., from Queen’s University Belfast in the United Kingdom, and colleagues evaluated three vision home-monitoring tests for patients to use to detect active nAMD versus diagnosing active nAMD at hospital follow-up during the after-treatment monitoring phase. The analysis included 259 patients (312 eyes; 50 years of age or older) with at least one eye first treated for active nAMD for six months to 42 months before approach.<\/p>\n The researchers found that median home-monitoring testing frequency was three times per month (range, one to four). The estimated area under the receiver operating characteristic curve was <0.6 for all home-monitoring tests (the KeepSight Journal, the MyVisionTrack mobile app, and the MultiBit app). Only the KeepSight Journal summary score was associated with lesion activity (odds ratio, 3.48).<\/p>\n “Results suggest that no home-monitoring vision test evaluated provided satisfactory diagnostic accuracy to identify active nAMD diagnosed in hospital eye service follow-up clinics,” the authors write. “Implementing any of these evaluated tests, with ophthalmologists only reviewing test positives, would mean most active lesions were missed, risking unnecessary sight loss.”<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n